Видео с ютуба Eunice Wang Md

AML on the Frontlines: Turning Trial Data Into Real-World Care

Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

Eunice Wang, MD, on Treating AML During the COVID-19 Pandemic

Professor Eunice Wang, M.D. - Phase III CASCADE study

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

Mechanisms of resistance to FLT3 inhibitors in AML and strategies to overcome this

KOMET-007: ziftomenib in combination with venetoclax and azacitidine in R/R AML

What Should I Do if I Have to Find a New Cancer Treatment Provider?

Eunice S. Wang, MD, discusses the Quantum First Study

Optimal therapy for patients who develop secondary AML after treatment with HMAs

Strategies to manipulate the immune system in myeloid malignancies

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

The value and utility of MRD in the management of adults with newly-diagnosed AML

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting